로딩 중…
StockDiggingStockDigging

Standard BioTools Inc.

LAB· NASDAQ
$0.77+5.45%
2026-09-18

Financials

Valuation Metrics

Standard BioTools Inc.'s Market Cap is $301M. At end of 2025 it was $493M. Ranked #2956 of 3,121 in US market (top 95%), #1337 of 1,463 on NASDAQ (top 91%), #187 of 205 in Health Care Equipment & Services (top 91%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$301M
Revenue$85M
Net Income$-87M
Total Assets$627M
Net Assets$540M
Employees387
Value
P/B0.56x
P/S3.55x
FCF Yield-27.48%
Profitability
ROE-16.18%
ROA-13.93%
Op. Margin-94.80%
Revenue Growth-36.71%
Financial Health
Debt Ratio16.16%
Total Debt$28M
FCF$-83M
Cash$270M
Current Ratio9.10x
Performance
1Y Return-45.40%
1M Return14.62%
From 52W High-55.24%
1Y MDD-61.79%
Trading
Volume1,843,764 shares
Trading Value$1M
Per Share
EPS$-0.22
BPS$1.38

Company Info

CEO Michael Egholm
Employees 387
HQ Boston, US

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.